Acadian Asset Management
ACAD icon

Acadian Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Acadian Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$986K Buy
39,023
+9,301
+31% +$205K ﹤0.01% 1267
2026
Q1 		$660K Sell
29,722
-90,020
-75% -$2.15M ﹤0.01% 1292
2025
Q4 		$3.19M Buy
119,742
+54,359
+83% +$1.3M 0.01% 780
2025
Q3 		$1.39M Buy
+65,383
New +$1.55M ﹤0.01% 975
2024
Q4 		– Sell
-4,156
Closed -$63K – 1585
2024
Q3 		$63K Sell
4,156
-2,728
-40% -$45.5K ﹤0.01% 1739
2024
Q2 		$111K Buy
+6,884
New +$111K ﹤0.01% 1515
2024
Q1 		– Sell
-1,280
Closed -$40K – 1544
2023
Q4 		$40K Sell
1,280
-7,604
-86% -$182K ﹤0.01% 1484
2023
Q3 		$184K Buy
+8,884
New +$241K ﹤0.01% 1205
2023
Q2 		– Sell
-11,628
Closed -$218K – 1698
2023
Q1 		$218K Buy
+11,628
New +$221K ﹤0.01% 1237
2021
Q3 		– Sell
-4,499
Closed -$110K – 1688
2021
Q2 		$110K Sell
4,499
-3,212
-42% -$72.5K ﹤0.01% 1610
2021
Q1 		$199K Buy
7,711
+4,683
+155% +$206K ﹤0.01% 1503
2020
Q4 		$162K Buy
3,028
+2,180
+257% +$108K ﹤0.01% 1620
2020
Q3 		$35K Sell
848
-137
-14% -$5.92K ﹤0.01% 1942
2020
Q2 		$48K Buy
+985
New +$47.3K ﹤0.01% 1928

Other funds holding ACAD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Acadian Asset Management's ACAD Position: Q2 2026 in Review

Acadian Asset Management increased its Acadia Pharmaceuticals (ACAD) stake by 31% in Q2 2026, buying an estimated $205K and bringing the position to 39,023 shares worth $986K. The position accounts for ﹤0.01% of the portfolio, ranked #1267.

Acadian Asset Management first reported a position in ACAD in Q2 2020 and has held it in 14 quarters since. The position peaked at $3.19M in Q4 2025. 290 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Acadian Asset Management held 39,023 shares of Acadia Pharmaceuticals worth $986K as of Q2 2026.
  • Acadian Asset Management bought 9,301 Acadia Pharmaceuticals shares in Q2 2026, an estimated $205K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1267 holding.
  • Acadian Asset Management first reported a position in Acadia Pharmaceuticals in Q2 2020 and has held it in 14 quarters since.
  • Acadian Asset Management's Acadia Pharmaceuticals position peaked at $3.19M in Q4 2025.
  • 290 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.